Efficacy of inebilizumab in N-MOmentum trial participants with or without prior immunosuppressants

This post hoc analysis examined the impact of prior immunosuppressants on the long-term efficacy and safety of inebilizumab, a cluster of differentiation 19 B-cell-depleting monoclonal antibody, in participants with aquaporin-4-seropositive neuromyelitis optica spectrum disorder from the N-MOmentum trial (NTC02200770). Inebilizumab treatment resulted in a sustained low annualized attack rate relative to the pretrial annualized attack rate and a high probability of remaining attack-free for up to 4 years among participants with and without prior immunosuppressant use. Based on modeling data, inebilizumab had greater long-term efficacy than historical immunosuppressants. Inebilizumab was well tolerated regardless of prior immunosuppressant use.